Drug Profile
Research programme: xB3 platform based therapeutics - biOasis Technologies
Alternative Names: xB3+Imiglucerase; xB3 - Trastuzumab; xB3 - 007; xB3 001; xB3 002; xB3 003; xb3 007; xB3+Cerezyme®Latest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator biOasis Technologies
- Class Antineoplastics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain metastases; Glioblastoma; Neurodegenerative disorders
- No development reported Gaucher's disease type II; Lysosomal storage diseases
Most Recent Events
- 08 Feb 2024 Preclinical development in Brain metastases is ongoing in Canada (biOasis pipeline, February 2024)
- 08 Feb 2024 Preclinical development in Neurodegenerative disorders is ongoing in Canada (biOasis pipeline, February 2024)
- 08 Feb 2024 Preclinical development in Glioblastoma is ongoing in Canada (biOasis pipeline, February 2024)